These ingredients may improve the immune microenvironment of obese patients with PCOS through targets such as TP53, AKT1, STAT3, JUN, and SRC and are based on pathways such as TRC signaling pathways, thereby improving clinical outcomes. Here, JUN is linked to polycystic ovary syndrome.